Elon's Vision
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Elon's Vision
No Result
View All Result
Home Stock

Former Minister Agnew Steps Down from Marshall Media Group Amid Uncertainty Over Telegraph Acquisition

by
July 18, 2024
in Stock
0
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

Lord Agnew, the former minister who resigned in 2022 over the handling of COVID loan fraud, has stepped down from his position at Old Queen Street Ventures – formerly known as UnHerd Ventures. This resignation, recorded in a filing at Companies House, has raised questions about the media group’s interest in The Daily Telegraph. Lord Agnew had been appointed as the chairman of UnHerd Ventures less…

Source

Previous Post

Possible revision: Preston North End in Discussions for Ownership Review at Championship Club

Next Post

Hundreds on streets in Leeds as unrest sparks police car flip and fire

Next Post

Hundreds on streets in Leeds as unrest sparks police car flip and fire

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest

Jay Bhattacharya on Public Health

October 12, 2021

Microsoft Planner vs Trello: Which Project Management Tool is Better?

May 24, 2023
Nicole Kidman Joins Paycom Webinar and Podcast to Talk Leadership, Tech and Work-Life Balance 

Nicole Kidman Joins Paycom Webinar and Podcast to Talk Leadership, Tech and Work-Life Balance 

January 31, 2025

An update on the National Nature Assessment

April 23, 2025
The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

0

0

0

0
The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

January 12, 2026
When Politics Replaces Policy: The Case for Reviving Limited Government

When Politics Replaces Policy: The Case for Reviving Limited Government

January 12, 2026
Bombing Iran Risks Repeating Past Mistakes

Bombing Iran Risks Repeating Past Mistakes

January 12, 2026
National Pharmacist Day: The Most Underused Clinicians in Health Care

National Pharmacist Day: The Most Underused Clinicians in Health Care

January 12, 2026

Recent News

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

January 12, 2026
When Politics Replaces Policy: The Case for Reviving Limited Government

When Politics Replaces Policy: The Case for Reviving Limited Government

January 12, 2026
Bombing Iran Risks Repeating Past Mistakes

Bombing Iran Risks Repeating Past Mistakes

January 12, 2026
National Pharmacist Day: The Most Underused Clinicians in Health Care

National Pharmacist Day: The Most Underused Clinicians in Health Care

January 12, 2026

Disclaimer: ElonsVision.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 ElonsVision. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 ElonsVision. All Rights Reserved.